Is therapy of people with chronic kidney disease ONTARGET?

Renovascular and renoprotective properties of telmisartan: clinical utility. Int J Nephrol Renovasc Dis (2010) 0.79

ONTARGET should not be over interpreted. Nephrol Dial Transplant (2009) 0.76

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 9.01

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83

Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation (2008) 6.30

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16

Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet (2011) 5.95

Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47

Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 4.99

Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91

Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86

Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83

Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73

Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68

Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58

Defining obesity cut points in a multiethnic population. Circulation (2007) 4.42

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet (2008) 4.37

Need for expertise based randomised controlled trials. BMJ (2005) 4.34

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33

Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med (2012) 4.32

Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med (2013) 4.27

Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation (2005) 4.21

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85

The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res (2006) 3.80

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67

Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens (2014) 3.66

Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64

Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J (2008) 3.52

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 3.43

Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J (2008) 3.38

Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2006) 3.38

Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35

The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 3.22

Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. Circulation (2008) 3.19

Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J (2007) 3.12

WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ (2005) 3.09

Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09

Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09

Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J (2002) 3.05

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation (2013) 3.02

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation (2008) 2.98

How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ (2005) 2.97

Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95

Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89

Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation (2010) 2.88

Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med (2011) 2.80

Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79

Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78

Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. J Am Coll Cardiol (2005) 2.76

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation (2010) 2.74

Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation (2012) 2.74

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73

Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72